Details for Patent: 6,433,003
Summary for Patent: 6,433,003
| Title: | Method for treating hyperhidrosis in mammals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | This invention is directed to methods for treating hyperhidrosis in mammals. Specifically, the methods of this invention involve the topical administration of glycopyrrolate compounds to humans. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Arthur M. Bobrove, Jeffrey D. Urman | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Rose U LLC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US09/552,011 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 6,433,003: Scope, Claim Construction, Expiration, and Hyperhidrosis Patent LandscapeUS Patent 6,433,003 covers methods of treating hyperhidrosis with topical or pharmaceutical compositions containing glycopyrrolate compounds at concentrations from approximately 0.25% to 6% by weight. The broadest practical protection is directed to treating an identified hyperhidrosis patient with a glycopyrrolate composition, rather than to a particular brand, formulation excipient, device, or manufacturing process. The patent term has expired, so US 6,433,003 no longer creates an enforceable US exclusion right. What does US Patent 6,433,003 cover?The patent covers glycopyrrolate-based treatment of excessive sweating, including facial, neck, and palmar hyperhidrosis. Its claims contain four principal limitations:
The patent is a method-of-treatment patent. It does not claim glycopyrrolate as a chemical compound, glycopyrrolate generally as an anticholinergic, or every possible hyperhidrosis formulation independent of concentration and use. How should the independent claims be construed?Claim 1: topical treatment of hyperhidrosisClaim 1 requires:
This claim is broad as to the affected body site, formulation excipients, dosing frequency, application schedule, and specific glycopyrrolate salt. Claims 3 and 4 separately identify facial/neck and palmar use, but those limitations do not appear in claim 1. A product would fall within the literal scope of claim 1 if its labeled or actual use involved topical treatment of hyperhidrosis with glycopyrrolate in the claimed concentration range. The claim does not require a prescription product, a particular container, a specific dosage volume, or a particular clinical scoring system. Claim 6: pharmaceutical composition administered to a humanClaim 6 covers a human method using a pharmaceutical composition containing 0.25% to approximately 6% glycopyrrolate and a pharmaceutically acceptable excipient. The claim does not expressly state "topically." That creates a potentially broader textual scope than claim 1. The specification, claim context, and prosecution history would control whether a court interprets claim 6 as limited to topical administration. A literal reading could reach routes beyond dermal delivery, but the patent's disclosed invention is centered on topical treatment of hyperhidrosis. Claim construction would therefore be material in any infringement dispute. Claims 5 and 7: glycopyrrolate salt limitationClaims 5 and 7 require a compound having the patent's Formula I, with X- defined as a pharmaceutically acceptable counterion. These claims narrow the glycopyrrolate definition to the disclosed formula and acceptable salt forms. The salt limitation can matter commercially. Glycopyrronium tosylate, glycopyrrolate bromide, and other salt forms may present different infringement and equivalence questions depending on the exact formula, claim language, prosecution history, and product composition. A salt is not automatically outside the patent merely because it differs from a named example. What is the claim-by-claim scope of US 6,433,003?
The claims do not expressly require:
What concentrations are protected?The concentration ranges are central to infringement analysis.
The use of "about" in claims 1 and 6 introduces tolerance around the endpoints. The scope cannot be determined solely by arithmetic. Courts would examine intrinsic evidence, including the specification, examples, prosecution amendments, and any arguments made to distinguish prior art. Claim 8 is narrower than claims 1 and 6. A product at 0.5% to 4.0% may satisfy both the broad independent claim and claim 8, assuming the remaining limitations are met. A product at 0.3% would potentially fall within claims 1 and 6 but not claim 8. What formulations are protected by US 6,433,003?The patent can reach multiple topical dosage forms if they contain the claimed glycopyrrolate concentration and are used to reduce hyperhidrosis. Potentially relevant forms include:
Claim 6 expressly requires a pharmaceutically acceptable excipient. Claim 1, as supplied, does not expressly impose that limitation. A commercially marketed product would ordinarily contain excipients, but the difference may affect claim interpretation and validity analysis. The patent does not appear, from the supplied claims, to require:
Later patents directed to specific salts, vehicles, packaging systems, delivery devices, stability profiles, or dosing regimens can create separate blocking rights even when US 6,433,003 has expired. When did US 6,433,003 lose exclusivity?US 6,433,003 was issued on August 13, 2002. Its US patent term was based on the applicable 20-year term measured from the relevant nonprovisional filing or international filing date, subject to patent-term adjustment and any terminal disclaimer. Public patent records identify the patent as expired after its statutory term. The patent therefore does not presently block generic, compounded, or branded topical glycopyrrolate products in the United States. [1] The expiration of US 6,433,003 does not eliminate later patent risk. A later product may still be covered by patents directed to:
What is the Orange Book status of US 6,433,003?US 6,433,003 is not the controlling Orange Book patent for current glycopyrronium products. Orange Book-listed patents are product-specific and must be assessed against the applicable NDA, dosage form, strength, and approved labeling. The patent number alone does not establish Orange Book listing status. Qbrexza, a glycopyrronium tosylate topical cloth, was approved by the FDA in 2018 for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Its product-specific patent estate is separate from US 6,433,003. [2, 3] Sofdra, a sofpironium topical gel, received FDA approval in 2024 for primary axillary hyperhidrosis in adults and pediatric patients 12 years of age and older. It has a different active ingredient and a separate patent portfolio. [4] Which products are commercially relevant to this patent landscape?
Qbrexza is the closest commercial comparator because it uses a topical glycopyrronium salt at 2.4%, within the concentration range stated in US 6,433,003. That technical overlap does not mean the older patent is the primary current barrier. The relevant analysis now shifts to Qbrexza-specific patents, regulatory exclusivity, Orange Book listings, and any later patents covering glycopyrronium tosylate delivery. What was the patent strength of US 6,433,003?Strengths at filing and during its termThe patent had several commercially important features:
Those features could have made the patent relevant to compounded preparations and early branded topical glycopyrrolate products. LimitationsThe estate also had limitations:
The expired status is now more commercially important than the original breadth. The patent has historical relevance but no current blocking value in the United States. Were there Paragraph IV challenges or settlements involving this patent?A Paragraph IV certification must be evaluated against the patents listed for a specific FDA-approved reference product. US 6,433,003 is not, by itself, a current Qbrexza or Sofdra patent strategy. A generic applicant would ordinarily direct a Paragraph IV challenge at patents listed for the relevant reference listed drug, not at an expired, non-listed patent. The supplied claim set does not establish a Paragraph IV filing, ANDA litigation, or settlement involving US 6,433,003. Any current challenge involving Qbrexza or Sofdra must be analyzed separately through the FDA Orange Book, district court complaints, docket entries, and settlement filings. [2, 5] Are biosimilar risks relevant?No. Biosimilar law does not apply to a small-molecule glycopyrrolate product. The relevant competitors are ANDA applicants, 505(b)(2) applicants, compounding pharmacies, branded topical products, and non-drug devices. Sofdra is not a biosimilar or generic equivalent to Qbrexza. It contains sofpironium, a different active ingredient, and competes through a separate NDA and patent estate. What geographic coverage does US 6,433,003 provide?US 6,433,003 provides only US patent rights. It does not directly control products sold in Canada, Europe, Japan, or other jurisdictions. Foreign counterparts must be analyzed independently for:
An expired US patent can coexist with live foreign counterpart patents, although the international family must be reviewed on a jurisdiction-by-jurisdiction basis. Key Takeaways
FAQsDoes US 6,433,003 cover Qbrexza?Technically, Qbrexza's 2.4% topical glycopyrronium tosylate product is close to the concentration and topical-use concepts in the patent. US 6,433,003 has expired, so it does not currently block Qbrexza or a competing product. Is a 2% topical glycopyrrolate product within the claimed range?Yes. A 2% product falls within the 0.25%-6% range of claims 1 and 6 and within the 0.5%-4.0% range of claim 8, subject to the other claim limitations. Is a 0.1% glycopyrrolate preparation covered?A 0.1% preparation is below the stated lower endpoint. It would not literally satisfy the numerical range, although historical infringement analysis could have required an equivalents assessment. The patent is expired. Does the patent cover oral glycopyrrolate for hyperhidrosis?Claim 6 does not expressly state a route, but claim construction would depend on the specification and prosecution history. Claim 1 expressly requires topical administration. The expired status makes the issue commercially immaterial for current US exclusion rights. Can a company market a topical glycopyrrolate product without a license to the patent owner?US 6,433,003 itself is expired, so no current license is required for that patent. A launch may still implicate later unexpired patents, FDA requirements, state pharmacy rules, product-specific Orange Book patents, and trademark rights. References
More… ↓ |
Drugs Protected by US Patent 6,433,003
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
